Hosking Partners’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$58M Sell
150,011
-2,429
-2% -$901K 1.93% 13
2026
Q1
$44.6M Buy
152,440
+7,892
+5% +$2.59M 1.6% 25
2025
Q4
$50.7M Buy
144,548
+2,166
+2% +$732K 1.72% 19
2025
Q3
$46M Buy
142,382
+65,307
+85% +$20.3M 1.67% 18
2025
Q2
$30M Sell
77,075
-476
-0.6% -$191K 1.19% 22
2025
Q1
$33.7M Sell
77,551
-686
-0.9% -$275K 1.42% 21
2024
Q4
$28.9M Sell
78,237
-10,018
-11% -$4.19M 1.13% 32
2024
Q3
$45.9M Sell
88,255
-15,233
-15% -$8.14M 1.77% 16
2024
Q2
$56.1M Sell
103,488
-8,926
-8% -$4.72M 2.08% 12
2024
Q1
$58.3M Sell
112,414
-338
-0.3% -$168K 2.15% 14
2023
Q4
$53.2M Sell
112,752
-7,985
-7% -$3.69M 2.24% 10
2023
Q3
$52.6M Buy
120,737
+20,267
+20% +$9.19M 2.33% 9
2023
Q2
$44.6M Buy
100,470
+9,039
+10% +$4.17M 1.89% 13
2023
Q1
$42M Sell
91,431
-18,492
-17% -$8.8M 1.95% 15
2022
Q4
$56.4M Buy
109,923
+53,695
+95% +$27.3M 2.28% 9
2022
Q3
$25.5M Sell
56,228
-3,522
-6% -$1.69M 1.11% 23
2022
Q2
$28.8M Sell
59,750
-11,457
-16% -$5.67M 1.14% 24
2022
Q1
$35M Sell
71,207
-1,627
-2% -$744K 0.9% 30
2021
Q4
$33.8M Sell
72,834
-1,381
-2% -$581K 0.82% 35
2021
Q3
$27.7M Sell
74,215
-8,303
-10% -$3.16M 0.69% 40
2021
Q2
$31.5M Sell
82,518
-1,136
-1% -$434K 0.7% 37
2021
Q1
$30M Sell
83,654
-3,194
-4% -$1.03M 0.71% 36
2020
Q4
$27.9M Sell
86,848
-3,069
-3% -$942K 0.72% 35
2020
Q3
$24.2M Sell
89,917
-3,051
-3% -$821K 0.74% 34
2020
Q2
$24.4M Sell
92,968
-6,768
-7% -$1.81M 0.75% 34
2020
Q1
$22.6M Sell
99,736
-3,246
-3% -$885K 0.79% 34
2019
Q4
$31.1M Sell
102,982
-3,988
-4% -$1.1M 0.76% 38
2019
Q3
$25.7M Sell
106,970
-5,269
-5% -$1.44M 0.67% 42
2019
Q2
$31.7M Sell
112,239
-769
-0.7% -$210K 0.77% 36
2019
Q1
$32.4M Sell
113,008
-578
-0.5% -$167K 0.82% 36
2018
Q4
$29.8M Buy
113,586
+11,494
+11% +$3.16M 0.85% 37
2018
Q3
$28M Sell
102,092
-2,972
-3% -$772K 0.62% 44
2018
Q2
$25M Sell
105,064
-20,040
-16% -$4.64M 0.55% 54
2018
Q1
$27.5M Buy
125,104
+5,486
+5% +$1.29M 0.61% 48
2017
Q4
$26.9M Buy
119,618
+8,278
+7% +$1.76M 0.62% 45
2017
Q3
$21.1M Buy
111,340
+327
+0.3% +$62.2K 0.55% 50
2017
Q2
$20.9M Buy
111,013
+1,795
+2% +$323K 0.55% 49
2017
Q1
$18.1M Buy
109,218
+9,858
+10% +$1.57M 0.5% 54
2016
Q4
$14.3M Sell
99,360
-2,569
-3% -$344K 0.46% 56
2016
Q3
$12.8M Buy
101,929
+12,334
+14% +$1.59M 0.43% 64
2016
Q2
$11.8M Buy
89,595
+23,100
+35% +$3.16M 0.49% 60
2016
Q1
$9.24M Buy
66,495
+4,937
+8% +$660K 0.42% 66
2015
Q4
$8.58M Buy
61,558
+801
+1% +$110K 0.4% 70
2015
Q3
$8.51M Buy
+60,757
New +$9.13M 0.41% 65

Other funds holding ELV

Hosking Partners's ELV Position: Q2 2026 in Review

Hosking Partners reduced its Elevance Health (ELV) stake by 1.6% in Q2 2026, selling an estimated $901K and leaving 150,011 shares worth $58M. The position accounts for 1.93% of the portfolio, ranked #13.

Hosking Partners first reported a position in ELV in Q3 2015 and has held it in 44 quarters since. The position peaked at $58.3M in Q1 2024. 1,600 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Hosking Partners held 150,011 shares of Elevance Health worth $58M as of Q2 2026.
  • Hosking Partners sold 2,429 Elevance Health shares in Q2 2026, an estimated $901K.
  • Elevance Health made up 1.93% of Hosking Partners's portfolio in Q2 2026, its #13 holding.
  • Hosking Partners first reported a position in Elevance Health in Q3 2015 and has held it in 44 quarters since.
  • Hosking Partners's Elevance Health position peaked at $58.3M in Q1 2024.
  • 1,600 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Hosking Partners's 13F filing for Q2 2026, filed 3 Aug 2026.